$2500 | Single User
$5000 | Site License
$7500 | Enterprise License

Melanoma - Pipeline Review, H2 2018 [Report Updated: 21-12-2018]

Published by Global Markets Direct: 21 Dec 2018 | 228692 | In Stock

Introduction

Melanoma - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Melanoma - Pipeline Review, H2 2018, provides an overview of the Melanoma (Oncology) pipeline landscape.

Melanoma is a tumor that develops as a result of the malignant transformation of melanocytes. These cells are derived from the neural crest. Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. It is more common in women than in men. In women, the most common site is the legs and melanomas in men are most common on the back. Unusual moles, sores, lumps, blemishes, markings, or changes in the way an area of the skin looks or feels are sign of melanoma. Treatment includes surgery, radiation and proton therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Melanoma - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 18, 126, 141, 1, 11, 223, 33 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 18, 16, 75 and 11 molecules, respectively.

Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Melanoma (Oncology).

- The pipeline guide reviews pipeline therapeutics for Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Melanoma (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Melanoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Melanoma (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
for Melanoma - Pipeline Review, H2 2018 [Report Updated: 21-12-2018]

  • Table of Contents

    Table of Contents 2

    Introduction 12

    Melanoma - Overview 13

    Melanoma - Therapeutics Development 14

    Melanoma - Therapeutics Assessment 80

    Melanoma - Companies Involved in Therapeutics Development 114

    Melanoma - Drug Profiles 240

    Melanoma - Dormant Projects 2161

    Melanoma - Discontinued Products 2195

    Melanoma - Product Development Milestones 2200

    Appendix 2213

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

228692 | GMDHC11021IDB

Number of Pages

2285

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Melanoma Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Ocular Melanoma Global Clinical Trials Review, H2, 2016
Ocular Melanoma Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial report, “O...
29 Jul 2016 by Global Data USD $2,500 More Info
NPS Melanoma (US)
IntroductionOne brand leads the pack in the US – but who is coming a close second?When it comes to m...
01 Jun 2016 by FirstWord Pharma USD $2,495 More Info
NPS Melanoma (EU5)
IntroductionOne brand is gaining ground in Europe – but who is coming a close second?When making mel...
01 Jun 2016 by FirstWord Pharma USD $2,495 More Info
Malignant Melanoma: Update Bulletin [April 2016]
Introduction...Gain new KOL insights on the latest events happening in Malignant melanoma (MM): expa...
01 Apr 2016 by FirstWord Pharma USD $995 More Info
Malignant Melanoma: Update Bulletin [Jan 2016]
IntroductionGain new KOL insights on the latest events happening in Malignant melanoma (MM): Opdivo’...
01 Jan 2016 by FirstWord Pharma USD $995 More Info
Malignant Melanoma: KOL Insight
IntroductionMalignant Melanoma: KOL Insight reveals the impact of immunotherapy on first-line treatm...
01 Nov 2015 by FirstWord Pharma USD $7,900 More Info
Physician Views: Will an Opdivo/Yervoy combination succeed in melanoma and can Keytruda keep pace in non-small-cell lung cancer?
Scope New data presented at the annual meeting of the American Association for Cancer Research (AACR...
23 Apr 2015 by FirstWord Pharma USD $695 More Info
Malignant Melanoma: KOL Insight
IntroductionMalignant Melanoma: PD-1 inhibitors revolutionise treatment is a comprehensive report wi...
17 Oct 2014 by FirstWord Pharma USD $7,900 More Info
Physician Views: Is GlaxoSmithKline's BRAF/MEK combo making headway in V600 mutation-positive melanoma patients?
Scope Although the clinical promise of cancer immunotherapies looks poised to see these products gai...
22 Jul 2014 by FirstWord Pharma USD $695 More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Melanoma - Pipeline Review, H2 2018 [Report Updated: 21-12-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data